High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism

References

• Redzic Z. Molecular biology of the blood–brain and the blood–cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 8(1), 3 (2011).
   Google Scholar
• Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10(2), 109–121 (2009).
   Google Scholar
• Linton MF, Gish R, Hubl ST et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88(1), 270–281 (1991).
   Google Scholar
• Riwanto M, Landmesser U. High-density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J. Lipid Res. 54(12), 3227–3243 (2013). • describes the modification of HDL function in cardiovascular disease.
   Google Scholar
• Toledo JB, Arnold SE, Raible K et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain 136(Pt 9), 2697–2706 (2013).
   Google Scholar
• Frank PG, Marcel YL. Apolipoprotein A-I: structure–function relationships. J. Lipid Res. 41(6), 853–872 (2000).
   Google Scholar
• Möckel B, Zinke H, Flach R, Weiss B, Weiler-Güttler H, Gassen HG. Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J. Neurochem. 62(2), 788–798 (1994).
   Google Scholar
• Stukas S, Robert J, Lee M et al. Intravenously Injected Human Apolipoprotein A-I Rapidly Enters the Central Nervous System via the Choroid Plexus. J. Am. Heart Assoc. 3(6), doi:10.1161/JAHA.114.001156 (2014).
   Google Scholar
• Elshourbagy NA, Liao WS, Mahley RW, Taylor JM. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl Acad. Sci. USA 82(1), 203–207 (1985).
   Google Scholar
• Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26(19), 4985–4994 (2006).
   Google Scholar
• Lane-Donovan C, Philips GT, Herz J. More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron 83(4), 771–787 (2014).
   Google Scholar
• Fitzgerald ML, Mendez AJ, Moore KJ, Andersson LP, Panjeton HA, Freeman MW. ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein’s first hydrophilic domain to the exoplasmic space. J. Biol. Chem. 276(18), 15137–15145 (2001).
   Google Scholar
• Puntoni M, Sbrana F, Bigazzi F, Sampietro T. Tangier disease: epidemiology, pathophysiology, and management. Am. J. Cardiovasc. Drugs 12(5), 303–311 (2012).
   Google Scholar
• Bodzioch M, Orsó E, Klucken J et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22(4), 347–351 (1999).
   Google Scholar
• McNeish J, Aiello RJ, Guyot D et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl Acad. Sci. USA 97(8), 4245–4250 (2000).
   Google Scholar
• Hirsch-Reinshagen V, Zhou S, Burgess BL et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279(39), 41197–41207 (2004).
   Google Scholar
• Wahrle SE, Jiang H, Parsadanian M et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280(52), 43236–43242 (2005).
   Google Scholar
• Cavelier C, Rohrer L, von Eckardstein A. ATP-Binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ. Res. 99(10), 1060–1066 (2006).
   Google Scholar
• Cavelier C, Ohnsorg PM, Rohrer L, von Eckardstein A. The β-chain of cell surface F(0)F(1) ATPase modulates apoA-I and HDL transcytosis through aortic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 32(1), 131–139 (2012).
   Google Scholar
• Rohrer L, Ohnsorg PM, Lehner M, Landolt F, Rinninger F, von Eckardstein A. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ. Res. 104(10), 1142–1150 (2009).
   Google Scholar
• Robert J, Lehner M, Frank S, Perisa D, von Eckardstein A, Rohrer L. Interleukin 6 stimulates endothelial binding and transport of high-density lipoprotein through induction of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 33(12), 2699–2706 (2013).
   Google Scholar
• Kozyraki R, Fyfe J, Kristiansen M et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat. Med. 5(6), 656–661 (1999).
   Google Scholar
• Hammad SM. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J. Biol. Chem. 275(16), 12003–12008 (2000).
   Google Scholar
• Kratzer I, Wernig K, Panzenboeck U et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood–brain barrier. J. Control. Release 117(3), 301–311 (2007).
   Google Scholar
• Rosenson RS, Brewer HB, Davidson WS et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125(15), 1905–1919 (2012).
   Google Scholar
• Shah AS, Tan L, Lu Long J, Davidson WS. The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54(10), 2575–2585 (2013). •• Emphasizes the complexity of the plasma HDL proteom.
   Google Scholar
• Riwanto M, Rohrer L, Roschitzki B et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127(8), 891–904 (2013).
   Google Scholar
• Jahangiri A. High-density lipoprotein and the acute phase response. Curr. Opin. Endocrinol. Diabetes Obes. 17(2), 156–160 (2010). • Provides information on HDL modification during the accute phase.
   Google Scholar
• Holzer M, Wolf P, Curcic S et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J. Lipid Res. 53(8), 1618–1624 (2012).
   Google Scholar
• Weichhart T, Kopecky C, Kubicek M et al. Serum amyloid A in uremic HDL promotes inflammation. J. Am. Soc. Nephrol. 23(5), 934–947 (2012).
   Google Scholar
• Demeester N, Castro G, Desrumaux C et al. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer’s disease. J. Lipid Res. 41(6), 963–974 (2000).
   Google Scholar
• Koch S, Donarski N, Goetze K et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42(7), 1143–1151 (2001). • Characterizes four lipoproteins in the CSF.
   Google Scholar
• Muffat J, Walker DW. Apolipoprotein D: an overview of its role in aging and age-related diseases. Cell Cycle 9(2), 269–273 (2010).
   Google Scholar
• Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9(2), 106–118 (2013). •• Provides comprehensive information regarding the common polymorphism in the apoE gene, and how they contribute differential risks to AD and other dementias. the known neurological functions of apoe are also summarized.
   Google Scholar
• Eisenberg DTA, Kuzawa CW, Hayes MG. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am. J. Phys. Anthropol. 143(1), 100–111 (2010).
   Google Scholar
• Chartier-Harlin MC, Parfitt M, Legrain S et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet. 3(4), 569–574 (1994).
   Google Scholar
• Houlden H, Crook R, Backhovens H et al. ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer’s disease families. Am. J. Med. Genet. 81(1), 117–121 (1998).
   Google Scholar
• Harold D, Abraham R, Hollingworth P et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat. Genet. 41(10), 1088–1093 (2009).
   Google Scholar
• Lambert J-C, Heath S, Even G et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat. Genet. 41(10), 1094–1099 (2009).
   Google Scholar
• Coon KD, Myers AJ, Craig DW et al. A high-density wholegenome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J. Clin. Psychiatry 68(4), 613–618 (2007).
   Google Scholar
• Bertram L, Lange C, Mullin K et al. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am. J. Hum. Genet. 83(5), 623–632 (2008).
   Google Scholar
• Burns LC, Minster RL, Demirci FY et al. Replication study of genome-wide associated SNPs with late-onset Alzheimer’s disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156B(4), 507–512 (2011).
   Google Scholar
• Wijsman EM, Pankratz ND, Choi Y et al. Genome-wide association of familial late-onset Alzheimer’s disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 7(2), e1001308 (2011).
   Google Scholar
• Kamboh MI, Demirci FY, Wang X et al. Genome-wide association study of Alzheimer’s disease. Transl. Psychiatry 2, e117 (2012).
   Google Scholar
• Kamboh MI, Barmada MM, Demirci FY et al. Genome-wide association analysis of age-at-onset in Alzheimer’s disease. Mol. Psychiatry 17(12), 1340–1346 (2012).
   Google Scholar
• Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43(8), 1467–1467 (1993).
   Google Scholar
• Apolipoprotein E genotyping in Alzheimer’s disease. National Institute on Aging/Alzheimer’s Association Working Group . Lancet 347(9008), 1091–1095 (1996).
   Google Scholar
• Sando SB, Melquist S, Cannon A et al. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer’s DISEASE;ACASECONTROLSTUDYFROMCENTRALNORWAY.BMC Neurol. 8, 9 (2008).
   Google Scholar
• Yoshizawa T, Yamakawa-Kobayashi K, Komatsuzaki Y et al. Dose-dependent association of apolipoprotein E allele epsilon 4 with late-onset, sporadic Alzheimer’s disease. Ann. Neurol. 36(4), 656–659 (1994).
   Google Scholar
• Brousseau T, Legrain S, Berr C, Gourlet V, Vidal O, Amouyel P. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer’s disease. Neurology 44(2), 342–344 (1994).
   Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123), 921–923 (1993).
   Google Scholar
• Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 342(8873), 697–699 (1993).
   Google Scholar
• Gomez-Isla T, West HL, Rebeck GW et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer’s disease. Ann. Neurol. 39(1), 62–70 (1996).
   Google Scholar
• Dai XY, Nanko S, Hattori M et al. Association of apolipoprotein E4 with sporadic Alzheimer’s disease is more pronounced in early onset type. Neurosci. Lett. 175(1–2), 74–76 (1994).
   Google Scholar
• Hyman BT, Gomez-Isla T, Rebeck GW et al. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer’s disease. Ann. NY Acad. Sci. 802, 1–5 (1996).
   Google Scholar
• Corder EH, Saunders AM, Risch NJ et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7(2), 180–184 (1994).
   Google Scholar
• Kok E, Haikonen S, Luoto T et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 65(6), 650–657 (2009).
   Google Scholar
• Polvikoski T, Sulkava R, Haltia M et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N. Engl. J. Med. 333(19), 1242–1247 (1995).
   Google Scholar
• Schmechel DE, Saunders AM, Strittmatter WJ et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90(20), 9649–9653 (1993).
   Google Scholar
• Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62(11), 1977–1983 (2004).
   Google Scholar
• Hultman K, Strickland S, Norris EH. The APOE 4/4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer’s disease patients. J. Cereb. Blood Flow Metab. 33(8), 1251–1258 (2013).
   Google Scholar
• Sunderland T, Mirza N, Putnam KT et al. Cerebrospinal fluid beta-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele. Biol. Psychiatry 56(9), 670–676 (2004).
   Google Scholar
• Morris JC, Roe CM, Xiong C et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 67(1), 122–131 (2010).
   Google Scholar
• Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59(3), 512–519 (2006).
   Google Scholar
• Risacher SL, Saykin AJ. Neuroimaging and other biomarkers for Alzheimer’s disease: the changing landscape of early detection. Annu. Rev. Clin. Psychol. 9, 621–648 (2013).
   Google Scholar
• Ramanan VK, Risacher SL, Nho K et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol. Psychiatry 19(3), 351–357 (2014).
   Google Scholar
• Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11(4), 575–580 (1993).
   Google Scholar
• Shao Y, Gearing M, Mirra SS. Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. J. Neuropathol. Exp. Neurol. 56(4), 376–381 (1997).
   Google Scholar
• Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541(1), 163–166 (1991).
   Google Scholar
• Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135(2), 235–238 (1992).
   Google Scholar
• LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269(38), 23403–23406 (1994).
   Google Scholar
• LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J. Biol. Chem. 270(16), 9039–9042 (1995).
   Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90(5), 1977–1981 (1993).
   Google Scholar
• Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer’s beta-amyloid. Biochem. Biophys. Res. Commun. 192(2), 359–365 (1993).
   Google Scholar
• Sanan DA, Weisgraber KH, Russell SJ et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94(2), 860–869 (1994).
   Google Scholar
• Aleshkov S, Abraham CR, Zannis VI. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1–40). Relevance to Alzheimer’s disease. Biochemistry 36(34), 10571–10580 (1997).
   Google Scholar
• Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68(2), 721–725 (1997).
   Google Scholar
• Hashimoto T, Serrano-Pozo A, Hori Y et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J. Neurosci. 32(43), 15181–15192 (2012).
   Google Scholar
• Verghese PB, Castellano JM, Garai K et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc. Natl Acad. Sci. USA 110(19), E1807–E1816 (2013).
   Google Scholar
• Deane R, Sagare A, Hamm K et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118(12), 4002–4013 (2008).
   Google Scholar
• Bales KR, Verina T, Dodel RC et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17(3), 263–264 (1997).
   Google Scholar
• Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32(14), 4803–4811 (2012).
   Google Scholar
• Kim J, Jiang H, Park S et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J. Neurosci. 31(49), 18007–18012 (2011).
   Google Scholar
• Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C. The binding of apoE to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry 53(40), 6323–6331 (2014).
   Google Scholar
• Nagy Z, Esiri MM, Jobst KA et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer’s disease. Neuroscience 69(3), 757–761 (1995).
   Google Scholar
• Ohm TG, Scharnagl H, März W, Bohl J. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions. Acta Neuropathol. 98(3), 273–280 (1999).
   Google Scholar
• Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer’s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl Acad. Sci. USA 98(15), 8838–8843 (2001).
   Google Scholar
• Rohn TT, Catlin LW, Coonse KG, Habig JW. Identification of an amino-terminal fragment of apolipoprotein E4 that localizes to neurofibrillary tangles of the Alzheimer’s disease brain. Brain Res. 1475, 106–115 (2012).
   Google Scholar
• Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci. Lett. 214(2–3), 163–166 (1996).
   Google Scholar
• Huey ED, Mirza N, Putnam KT et al. Stability of CSF beta-amyloid(1–42) and tau levels by APOE genotype in Alzheimer patients. Dement. Geriatr. Cogn. Disord. 22(1), 48–53 (2006).
   Google Scholar
• Sacre SM, Stannard AK, Owen JS. Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells. FEBS Lett. 540(1–3), 181–187 (2003).
   Google Scholar
• Hafezi-Moghadam A, Thomas KL, Wagner DD. ApoE deficiency leads to a progressive age-dependent blood–brain barrier leakage. Am. J. Physiol. Cell Physiol. 292(4), C1256–C1262 (2007).
   Google Scholar
• Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood–brain barrier model. J. Biol. Chem. 286(20), 17536–17542 (2011).
   Google Scholar
• Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18), 1993–2000 (2009).
   Google Scholar
• Kawano M, Kawakami M, Otsuka M, Yashima H, Yaginuma T, Ueki A. Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer’s disease. Clin. Chim. Acta 239(2), 209–211 (1995).
   Google Scholar
• Kuriyama M, Takahashi K, Yamano T et al. Low levels of serum apolipoprotein A I and A II in senile dementia. Jpn J. Psychiatry Neurol. 48(3), 589–593 (1994).
   Google Scholar
• Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol. Aging 21(1), 27–30 (2000).
   Google Scholar
• Vollbach H, Heun R, Morris CM et al. APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann. Neurol. 58(3), 436–441 (2005).
   Google Scholar
• Smach MA, Edziri H, Charfeddine B et al. Polymorphism in apoA1 influences high-density lipoprotein cholesterol levels but is not a major risk factor of alzheimer’s disease. Dement. Geriatr. Cogn. Dis. Extra 1(1), 249–257 (2011).
   Google Scholar
• Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease. Brain Res. Mol. Brain Res. 118(1–2), 140–146 (2003).
   Google Scholar
• Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease. Biomarkers 14(7), 493–501 (2009).
   Google Scholar
• Castaño EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer’s disease and non-demented elderly subjects. Neurol. Res. 28(2), 155–163 (2006).
   Google Scholar
• Song H, Saito K, Seishima M, Noma A, Urakami K, Nakashima K. Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer’s disease. Neurosci. Lett. 231(3), 175–178 (1997).
   Google Scholar
• Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ. Brain expression of apolipoproteins E, J, and A-I in Alzheimer’s disease. J. Neurochem. 66(6), 2429–2435 (1996).
   Google Scholar
• Lefterov I, Fitz NF, Cronican AA et al. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J. Biol. Chem. 285(47), 36945–36957 (2010).
   Google Scholar
• Lewis TL, Cao D, Lu H et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J. Biol. Chem. 285(47), 36958–36968 (2010).
   Google Scholar
• Paula-Lima AC, Tricerri MA, Brito-Moreira J et al. Human apolipoprotein A-I binds amyloid-beta and prevents Abetainduced neurotoxicity. Int. J. Biochem. Cell Biol. 41(6), 1361–1370 (2009).
   Google Scholar
• Borja MS, Zhao L, Hammerson B et al. HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS ONE 8(8), e71541 (2013).
   Google Scholar
• Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem. Res. Toxicol. 23(3), 447–454 (2010).
   Google Scholar
• Shao B, Tang C, Heinecke JW, Oram JF. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J. Lipid Res. 51(7), 1849–1858 (2010).
   Google Scholar
• Wu Z-C, Yu J-T, Li Y, Tan L. Clusterin in Alzheimer’s disease. Adv. Clin. Chem. 56, 155–173 (2012).
   Google Scholar
• Fan J, Stukas S, Wong C et al. An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia. J. Lipid Res. 52(9), 1605–1616 (2011).
   Google Scholar
• Wilson MR, Yerbury JJ, Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol. Biosyst. 4(1), 42–52 (2008).
   Google Scholar
• DeMattos RB, Cirrito JR, Parsadanian M et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 41(2), 193–202 (2004).
   Google Scholar
• Cole GM, Ard MD. Influence of lipoproteins on microglial degradation of Alzheimer’s amyloid beta-protein. Microsc. Res. Tech. 50(4), 316–324 (2000).
   Google Scholar
• Hammad SM, Ranganathan S, Loukinova E, Twal WO, Argraves WS. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J. Biol. Chem. 272(30), 18644–18649 (1997).
   Google Scholar
• Bartl MM, Luckenbach T, Bergner O, Ullrich O, Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp. Cell Res. 271(1), 130–141 (2001).
   Google Scholar
• Kirszbaum L, Bozas SE, Walker ID. SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett. 297(1–2), 70–76 (1992).
   Google Scholar
• Kang S-W, Shin Y-J, Shim Y-J, Jeong S-Y, Park I-S, Min B-H. Clusterin interacts with SCLIP (SCG10-like protein) and promotes neurite outgrowth of PC12 cells. Exp. Cell Res. 309(2), 305–315 (2005).
   Google Scholar
• Sarma JV, Ward PA. The complement system. Cell Tissue Res. 343(1), 227–235 (2011).
   Google Scholar
• Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J. Complement receptor 1 (CR1) and Alzheimer’s disease. Immunobiology 217(2), 244–250 (2012). •• Provides detailed information regarding the genetic and protein structure of the complement receptor 1, and how its polymorphism may influence AD risk.
   Google Scholar
• Eikelenboom P, van Exel E, Veerhuis R, Rozemuller AJM, van Gool WA, Hoozemans JJM. Innate immunity and the etiology of late-onset Alzheimer’s disease. Neurodegener. Dis. 10(1–4), 271–273 (2012).
   Google Scholar
• Eikelenboom P, Stam FC. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer’s dementia. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 47(1), 17–25 (1984).
   Google Scholar
• McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107(1–3), 341–346 (1989).
   Google Scholar
• Rogers J, Schultz J, Brachova L et al. Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer’s disease. Res. Immunol. 143(6), 624–630 (1992).
   Google Scholar
• Fan R, DeFilippis K, Van Nostrand WE. Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition. J. Neuroinflammation. 4, 22 (2007).
   Google Scholar
• Wirz KTS, Bossers K, Stargardt A et al. Cortical beta amyloid protein triggers an immune response, but no synaptic changes in the APPswe/PS1dE9 Alzheimer’s disease mouse model. Neurobiol. Aging 34(5), 1328–1342 (2013).
   Google Scholar
• Strohmeyer R, Shen Y, Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer’s disease brain. Brain Res. Mol. Brain Res. 81(1–2), 7–18 (2000).
   Google Scholar
• Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer’s disease brain. Am. J. Pathol. 154(3), 927–936 (1999).
   Google Scholar
• Watson MD, Roher AE, Kim KS, Spiegel K, Emmerlin MR. Complement interactions with amyloid β1–42: a nidus for inflammation in AD brains. Amyloid 4(3), 147–156 (1997).
   Google Scholar
• Smyth MD, Cribbs DH, Tenner AJ et al. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol. Aging 15(5), 609–614.
   Google Scholar
• Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer’s disease. J. Neurosci. 24(29), 6457–6465 (2004).
   Google Scholar
• Wyss-Coray T, Yan F, Lin AH-T et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc. Natl Acad. Sci. USA 99(16), 10837–10842 (2002).
   Google Scholar
• Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28(25), 6333–6341 (2008).
   Google Scholar
• Thambisetty M, Simmons A, Velayudhan L et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 67(7), 739–748 (2010).
   Google Scholar
• Zhang R, Barker L, Pinchev D et al. Mining biomarkers in human sera using proteomic tools. Proteomics 4(1), 244–256 (2004).
   Google Scholar
• Kiddle SJ, Thambisetty M, Simmons A et al. Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS ONE 7(9), e44260 (2012).
   Google Scholar
• Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer’s disease. Brain 129(Pt 11), 3042–3050 (2006).
   Google Scholar
• Thambisetty M, Hye A, Foy C et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease. J. Neurol. 255(11), 1712–1720 (2008).
   Google Scholar
• Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 33(1), 7–22 (2014).
   Google Scholar
• Hoozemans JJM, Rozemuller AJM, van Haastert ES, Eikelenboom P, van Gool WA. Neuroinflammation in Alzheimer’s disease wanes with age. J. Neuroinflammation. 8, 171 (2011).
   Google Scholar
• Khovidhunkit W, Kim M-S, Memon RA et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45(7), 1169–1196 (2004).
   Google Scholar
• Kindy MS, Yu J, Guo J-T, Zhu H. Apolipoprotein serum amyloid A in alzheimer’s disease. J. Alzheimers. Dis. 1(3), 155–167 (1999).
   Google Scholar
• Miida T, Yamada T, Seino U et al. Serum amyloid A (SAA)-induced remodeling of CSF-HDL. Biochim. Biophys. Acta 1761(4), 424–433 (2006).
   Google Scholar
• Tölle M, Huang T, Schuchardt M et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc. Res. 94(1), 154–162 (2012).
   Google Scholar
• Cortes-Canteli M, Paul J, Norris EH et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer’s disease. Neuron 66(5), 695–709 (2010).
   Google Scholar
• Jantaratnotai N, Schwab C, Ryu JK, McGeer PL, McLarnon JG. Converging perturbed microvasculature and microglial clusters characterize Alzheimer disease brain. Curr. Alzheimer Res. 7(7), 625–636 (2010).
   Google Scholar
• Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc. Natl Acad. Sci. USA 107(50), 21812–21817 (2010).
   Google Scholar
• Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH. Fibrinogen and altered hemostasis in Alzheimer’s disease. J. Alzheimers Dis. 32(3), 599–608 (2012).
   Google Scholar
• Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer’s disease. J. Exp. Med. 204(8), 1999–2008 (2007).
   Google Scholar
• Piers TM, Heales SJ, Pocock JM. Positive allosteric modulation of metabotropic glutamate receptor 5 down-regulates fibrinogen-activated microglia providing neuronal protection. Neurosci. Lett. 505(2), 140–145 (2011).
   Google Scholar
• Ryu JK, McLarnon JG. A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J. Cell. Mol. Med. 13(9A), 2911–2925 (2009).
   Google Scholar
• Arai T, Miklossy J, Klegeris A, Guo J-P, McGeer PL. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 65(1), 19–25 (2006).
   Google Scholar
• Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in brains of patients with Alzheimer’s disease. Neurosci. Lett. 146(2), 152–154 (1992).
   Google Scholar
• Tripathy D, Sanchez A, Yin X, Luo J, Martinez J, Grammas P. Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. Front. Aging Neurosci. 5, 19 (2013).
   Google Scholar
• Arai T, Guo J-P, McGeer PL. Proteolysis of nonphosphorylated and phosphorylated tau by thrombin. J. Biol. Chem. 280(7), 5145–5153 (2005).
   Google Scholar